Last-Resort hope: modified herpes virus plus immunotherapy for advanced melanoma
NCT ID NCT06590480
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab to adults with advanced melanoma that has worsened after anti-PD-1 treatment. The goal is to offer potential benefit to patients who have few options left. Data will be collected in real-world settings to understand how the combination works outside of formal clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vusolimogene oderparepvec (a genetically modified herpes virus) plus nivolumab (an immunotherapy drug)
What this could lead to
If this treatment helps, it could offer a new option for people with advanced melanoma that has stopped responding to standard immunotherapy.
What could go wrong
This is an expanded access program, not a formal trial, so results are collected in real-world settings and may not prove effectiveness. The virus-based therapy may cause side effects like flu-like symptoms or injection site reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.